Literature DB >> 26253253

[Step-by-step toward the perfect hepatitis C treatment for all genotypes].

M Cornberg1, S Nitschmann.   

Abstract

Entities:  

Year:  2015        PMID： 26253253     DOI： 10.1007/s00108-015-3774-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  12 in total

1.  Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.

Authors:  Christophe Hézode; Tarik Asselah; K Rajender Reddy; Tarek Hassanein; Marina Berenguer; Katarzyna Fleischer-Stepniewska; Patrick Marcellin; Coleen Hall; Gretja Schnell; Tami Pilot-Matias; Niloufar Mobashery; Rebecca Redman; Regis A Vilchez; Stanislas Pol
Journal:  Lancet       Date:  2015-03-31       Impact factor: 79.321

Review 2.  [All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].

Authors:  C Höner zu Siederdissen; M Cornberg
Journal:  Dtsch Med Wochenschr       Date:  2014-11-12       Impact factor: 0.628

3.  Sofosbuvir: the final nail in the coffin for hepatitis C?

Authors:  Michael P Manns; Markus Cornberg
Journal:  Lancet Infect Dis       Date:  2013-03-15       Impact factor: 25.071

4.  Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease.

Authors:  Benjamin Maasoumy; Kerstin Port; Katja Deterding; Christoph Höner Zu Siederdissen; Antoaneta A Markova; Magdalena Rogalska-Taranta; Michael P Manns; Heiner Wedemeyer; Markus Cornberg
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-08       Impact factor: 2.566

5.  Strategies to manage hepatitis C virus (HCV) disease burden.

Authors:  H Wedemeyer; A S Duberg; M Buti; W M Rosenberg; S Frankova; G Esmat; N Örmeci; H Van Vlierberghe; M Gschwantler; U Akarca; S Aleman; I Balık; T Berg; F Bihl; M Bilodeau; A J Blasco; C E Brandão Mello; P Bruggmann; F Calinas; J L Calleja; H Cheinquer; P B Christensen; M Clausen; H S M Coelho; M Cornberg; M E Cramp; G J Dore; W Doss; M H El-Sayed; G Ergör; C Estes; K Falconer; J Félix; M L G Ferraz; P R Ferreira; J García-Samaniego; J Gerstoft; J A Giria; F L Gonçales; M Guimarães Pessôa; C Hézode; S J Hindman; H Hofer; P Husa; R Idilman; M Kåberg; K D E Kaita; A Kautz; S Kaymakoglu; M Krajden; H Krarup; W Laleman; D Lavanchy; P Lázaro; R T Marinho; P Marotta; S Mauss; M C Mendes Correa; C Moreno; B Müllhaupt; R P Myers; V Nemecek; A L H Øvrehus; J Parkes; K M Peltekian; A Ramji; H Razavi; N Reis; S K Roberts; F Roudot-Thoraval; S D Ryder; R Sarmento-Castro; C Sarrazin; D Semela; M Sherman; G E Shiha; J Sperl; P Stärkel; R E Stauber; A J Thompson; P Urbanek; P Van Damme; I van Thiel; D Vandijck; W Vogel; I Waked; N Weis; J Wiegand; A Yosry; A Zekry; F Negro; W Sievert; E Gower
Journal:  J Viral Hepat       Date:  2014-05       Impact factor: 3.728

6.  Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.

Authors:  Jean-Michel Molina; Chloe Orkin; David M Iser; Francisco-Xavier Zamora; Mark Nelson; Christoph Stephan; Benedetta Massetto; Anuj Gaggar; Liyun Ni; Evguenia Svarovskaia; Diana Brainard; G Mani Subramanian; John G McHutchison; Massimo Puoti; Jürgen K Rockstroh
Journal:  Lancet       Date:  2015-02-04       Impact factor: 79.321

7.  European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.

Authors:  J K Rockstroh; S Bhagani; Y Benhamou; R Bruno; S Mauss; L Peters; M Puoti; V Soriano; C Tural
Journal:  HIV Med       Date:  2008-02       Impact factor: 3.180

8.  Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.

Authors:  Eric Lawitz; Edward Gane; Brian Pearlman; Edward Tam; Wayne Ghesquiere; Dominique Guyader; Laurent Alric; Jean-Pierre Bronowicki; Laura Lester; William Sievert; Reem Ghalib; Luis Balart; Fredrik Sund; Martin Lagging; Frank Dutko; Melissa Shaughnessy; Peggy Hwang; Anita Y M Howe; Janice Wahl; Michael Robertson; Eliav Barr; Barbara Haber
Journal:  Lancet       Date:  2014-11-11       Impact factor: 202.731

9.  Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.

Authors:  Mark Sulkowski; Christophe Hezode; Jan Gerstoft; John M Vierling; Josep Mallolas; Stanislas Pol; Marcelo Kugelmas; Abel Murillo; Nina Weis; Ronald Nahass; Oren Shibolet; Lawrence Serfaty; Marc Bourliere; Edwin DeJesus; Eli Zuckerman; Frank Dutko; Melissa Shaughnessy; Peggy Hwang; Anita Y M Howe; Janice Wahl; Michael Robertson; Eliav Barr; Barbara Haber
Journal:  Lancet       Date:  2014-11-11       Impact factor: 202.731

10.  Global distribution and prevalence of hepatitis C virus genotypes.

Authors:  Jane P Messina; Isla Humphreys; Abraham Flaxman; Anthony Brown; Graham S Cooke; Oliver G Pybus; Eleanor Barnes
Journal:  Hepatology       Date:  2014-07-28       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.